NCT01684709

Brief Summary

This study compares the medical and psychological effects of telemonitoring plus intensified self-management support to those of usual care alone for patients with poorly controlled type 2 diabetes mellitus (DM). If this intervention proves effective without increasing costs or clinician burden, then its implementation could yield major public health benefits, especially for vulnerable and underserved DM patients, and broader societal benefit may occur through increased helping behavior and strengthened social ties.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
864

participants targeted

Target at P75+ for not_applicable type-2-diabetes-mellitus

Timeline
Completed

Started Dec 2012

Longer than P75 for not_applicable type-2-diabetes-mellitus

Geographic Reach
1 country

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 22, 2012

Completed
22 days until next milestone

First Posted

Study publicly available on registry

September 13, 2012

Completed
3 months until next milestone

Study Start

First participant enrolled

December 1, 2012

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 26, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 26, 2017

Completed
Last Updated

October 25, 2017

Status Verified

October 1, 2017

Enrollment Period

4.8 years

First QC Date

August 22, 2012

Last Update Submit

October 23, 2017

Conditions

Keywords

Type 2 DiabetesInformal CaregiversSelf CareQuality of LifeHealth Information Technology

Outcome Measures

Primary Outcomes (1)

  • 12-month glycemic control

    H1 (Primary biological outcome): Compared to DM patients randomized to control, those randomized to intervention will have a 0.3% greater improvement in HbA1c units.

    12 months

Secondary Outcomes (1)

  • Secondary effects upon adjustment to diabetes

    12 months

Study Arms (2)

Telemonitoring + self-management support

EXPERIMENTAL

Automated assessment calls with follow-up by a Care Manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up.

Behavioral: Telemonitoring + self-management support

Usual Care

NO INTERVENTION

Usual Care

Interventions

Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up

Telemonitoring + self-management support

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • type 2 DM (hospitalization or outpatient visit within 12 months for \>2 ICD9 codes of 250.xx or therapeutic class codes C4G, C4K, or C4L in past 2 years' problem list)
  • poor glycemic control (recent HbA1c% \>7.5)
  • at least 21 years old
  • fluent in English
  • can use telephone numeric touchtone keypad
  • can identify 1-4 eligible CPs
  • not in palliative care, on transplant waitlist, or at high risk for 1-year mortality
  • free of major psychiatric or cognitive impairment.
  • ICGs: We will stratify recruitment within sites so that 50% of enrolled patients have an ICG.
  • Patients with an ICG cannot enroll unless their ICG also provides consent.
  • has a CP that resides in continental US but outside patient's household; has communicated with patient, in person or by phone, at least once monthly over preceding 6 months; has a home telephone or mobile cell phone; has an internet connection; can communicate via e-mail; is free of severe psychiatric/cognitive impairment; is fluent in English; and is at least 21 years of age.

You may not qualify if:

  • Limited life expectancy (e.g., advanced stage cancer/heart failure/on oxygen/end stage renal disease), receiving palliative care
  • active alcohol or drug abuse
  • dementia, bipolar disorder, schizophrenia
  • unable to speak English
  • not planning to get all or most of care at study site
  • primary care physician not affiliated with study site
  • unable to use a telephone to respond to weekly automated self-management support calls
  • unable to nominate an eligible CP
  • ICG (if present) does not consent to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

University of Michigan

Ann Arbor, Michigan, 48105, United States

Location

Hamilton Health Center

Flint, Michigan, 48504, United States

Location

Center for Family Health

Jackson, Michigan, 49201, United States

Location

Alcona Health Center

Lincoln, Michigan, 48742, United States

Location

Muskegon Family Care

Muskegon Heights, Michigan, 49444, United States

Location

St. John Masonic Medical Center

Saint Clair Shores, Michigan, 48082, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • James E Aikens, PhD

    University of Michigan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Family Medicine

Study Record Dates

First Submitted

August 22, 2012

First Posted

September 13, 2012

Study Start

December 1, 2012

Primary Completion

September 26, 2017

Study Completion

September 26, 2017

Last Updated

October 25, 2017

Record last verified: 2017-10

Locations